Evidence for TORC1 activation marker as a predictive factor for everolimus: Dr Thomas Bachelot - Centre Leon Berard, France

Update: 2012-05-30

Description

A new analysis may help doctors identify breast cancer patients who will benefit from treatment with the immune suppressant drug everolimus, said French researchers at the 4th IMPAKT Breast Cancer Conference in Brussels, Belgium.

Everolimus is currently used as an immunosuppressant to prevent patients rejecting transplanted organs and in the treatment of renal cell cancer.

Research is also being conducted into the drug’s use in other cancers, including breast cancer.

Dr Thomas Bachelot, from Centre Leon Berard in Lyon and colleagues analyzed data from the TAMRAD study, published two years ago

Comments

In Channel

PI3K and the heterogeneity of small tumour breast cancer: Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium

2012-05-3005:06

Metabolism in malignant tumors: Prof Tak Mak - University of Toronto, Canada

2012-05-3008:32

Evidence for TORC1 activation marker as a predictive factor for everolimus: Dr Thomas Bachelot - Centre Leon Berard, France

2012-05-3007:24

Targeting DNA damage response and repair for triple negative breast cancer: Prof Thomas Helleday - Karolinska Institutet, Swede

2012-05-3005:55

New cyclin-dependent kinase inhibitor with letrozole for ER+/HER2- breast cancer: Prof Richard Finn - Universtity of California

2012-05-2907:56

Endocrine therapy and endocrine resistant breast cancer: Prof Mitch Dowsett – The Institute for Cancer Research, London, UK

2012-05-2907:33

Neoadjuvant therapy and PCR through chemotherapy prior to surgery: Dr Michail Ignatiadis – Jules Bordet Institute, Belgium

2012-05-2906:34

Endocrine therapy resistance and next generation sequencing: Prof Matthew Ellis - Washington University, USA

2012-05-2909:49

Highlights and goals of IMPAKT 2012: Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium

2012-05-2906:23

Targeting the PI3K/mTOR pathway: Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA

2012-05-2906:37

Overcoming drug resistance and targeting critical pathways: Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New Yor

2012-05-2907:53

Molecularly characterising triple negative breast cancer: Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium

2012-05-2905:07

Recent developments in neoadjuvant therapy: Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany

2012-05-2912:11

Heterogeneity of tumours and the challenges of biomarker development: Prof Giuseppe Curigliano – IEO, Milan, Italy

2012-05-2908:50

Minimising recurrence by using most effective treatment: Prof Fabrice Andre – Institut Gustave Roussy, Paris, France

2012-05-2811:11

Criteria required before implementation of whole genome arrays in clinical practice: Prof Daniel Hays - University of Michigan

2012-05-2806:18

Cancer genes differ in different parts of a tumour: Prof Charles Swanton - CRUK London Research Institute and UCL, UK

2012-05-2807:08

Prognostic significance of progesterone receptor+ tumour cells: Dr Aleix Prat - University of North Carolina

2012-05-2805:54

Use of metformin against breast cancer: Prof Alastair Thompson – University of Dundee, UK

2012-05-2806:59

00:00

Evidence for TORC1 activation marker as a predictive factor for everolimus: Dr Thomas Bachelot - Centre Leon Berard, France

#box-pro-ellipsis-17606834051939{-webkit-line-clamp:2;}Evidence for TORC1 activation marker as a predictive factor for everolimus: Dr Thomas Bachelot - Centre Leon Berard, France

Evidence for TORC1 activation marker as a predictive factor for everolimus: Dr Thomas Bachelot - Centre Leon Berard, France

ecancer.org

Evidence for TORC1 activation marker as a predictive factor for everolimus: Dr Thomas Bachelot - Centre Leon Berard, France